Masses of the liver

Sternberg's Diagnostic Surgical Pathology: Sixth Edition

Volumn 2-2, Issue , 2015, Pages

  Washington, Kay ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84975113209     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (366)

1. Takamori R, Wong LL, Dang C, et al. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transpl 2000;6:67-72.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
3. Colecchia A, Montrone L, Scaioli E, et al. Percutaneous liver biopsy in the clinical management of hepatocellular carcinoma: back to the future. Hepatology 2011;53:2147.
4. Elsayes KM, Ellis JH, Elkhouly T, et al. Diagnostic yield of percutaneous image-guided tissue biopsy of focal hepatic lesions in cancer patients: ten percent are not metastases from the primary malignancy. Cancer 2011;117:4041-4048.
5. Ma X, Arellano RS, Gervais DA, et al. Success of image-guided biopsy for small (=3 cm) focal liver lesions in cirrhotic and noncirrhotic individuals. J Vasc Interv Radiol 2010;21:1539-1547.
6. Wyatt J, Hübscher S, Goldin R. Standards and Datasets for Reporting Cancers: Dataset for Histopathology Reporting of Liver Resection Specimens (Including Gall Bladder) and Liver Biopsies for Primary and Metastatic Carcinoma. 2nd ed. London, United Kingdom: The Royal College of Pathologists, 2012. http://www.rcpath.org/Resources/RCPath/Migrated%20Resources/Documents/G/G050_LiverDataset_Jun12.pdf. Accessed May 27, 2014
7. Rakha E, Ramaiah S, McGregor A. Accuracy of frozen section in the diagnosis of liver mass lesions. J Clin Pathol 2006;59:352-354.
8. Dhir M, Lyden ER, Wang A, et al. Influence of margins on overall survival after hepatic resection for colorectal metastasis: a meta-analysis. Ann Surg 2011;254:234-242.
9. Poultsides GA, Schulick RD, Pawlik TM. Hepatic resection for colorectal metastases: the impact of surgical margin status on outcome. HPB 2010;12:43-49.
10. Muratore A, Ribero D, Zimmitti G, et al. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol 2010;17:1324-1329.
11. Ceyhan K, Kupana SA, Bekta M, et al. The diagnostic value of on-site cytopathological evaluation and cell block preparation in fine-needle aspiration cytology of liver masses. Cytopathology 2006;17:267-274.
12. Bakshi P, Srinivasan R, Rao KLN, et al. Fine needle aspiration biopsy in pediatric space-occupying lesions of liver: a retrospective study evaluating its role and diagnostic efficacy. J Pediatr Surg 2006;41:1903-1908.
13. Franca AVC, Valerio HMG, Trevisan M, et al. Fine needle aspiration biopsy for improving the diagnostic accuracy of cut needle biopsy of focal liver lesions. Acta Cytol 2003;47:332-336.
14. Arnason T, Fleming KE, Wanless IR. Peritumoral hyperplasia of the liver: a response to portal vein invasion by hypervascular neoplasms. Histopathology 2013;62:458-464.
15. Gerber MA, Thung SN, Bodenheimer HC, Jr., et al. Characteristic histologic triad in liver adjacent to metastatic neoplasm. Liver 1986;6:85-88.
16. Wuerz T, Kane JB, Boggild AK, et al. A review of amoebic liver abscess for clinicians in a nonendemic setting. Can J Gastroenterol 2012;26:729-733.
17. Wiwanitkit V, Suwansaksri N, Suwansaksri J. Causative agents of liver abscess in those with liver cirrhosis: a 10 year case review of hospitalized patients in Thailand. Ann Trop Med Parasitol 2002;96:513-516.
18. Congly SE, Shaheen AAM, Meddings L, et al. Amoebic liver abscess in USA: a population-based study of incidence, temporal trends and mortality. Liver Int 2011;31:1191-1198.
19. Seeto RK, Rockey DC. Amebic liver abscess: epidemiology, clinical features, and outcome. West J Med 1999;170:104-109.
20. Duggal P, Guo X, Haque R, et al. A mutation in the leptin receptor is associated with Entamoeba histolytica infection in children. J Clin Invest 2011;121:1191-1198.
21. Salles JM, Moraes LA, Salles MC. Hepatic amebiasis. Braz J Infect Dis 2003;7:96-110.
22. Hamzah Z, Petmitr S, Mungthin M, et al. Differential detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii by a single-round PCR assay. J Clin Microbiol 2006;44:3196-200.
23. Haque R, Kabir M, Noor Z, et al. Diagnosis of amebic liver abscess and amebic colitis by detection of Entamoeba histolytica DNA in blood, urine, and saliva by a real-time PCR assay. J Clin Microbiol 2010;48:2798-2801.
24. Wells CD, Arguedas M. Amebic liver abscess. South Med J 2004;97:673-682.
25. Meddings L, Myers RP, Hubbard J, et al. A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol 2010;105:117-124.
26. Rahimian J, Wilson T, Oram V, et al. Pyogenic liver abscess: recent trends in etiology and mortality. [see comment]. Clin Infect Dis 2004;39:1654-1659.
27. Seeto RK, Rockey DC. Pyogenic liver abscess: changes in etiology, management, and outcome. Medicine 1996;75:99-113.
28. Thomsen RW, Jepsen P, Sorensen HT. Diabetes mellitus and pyogenic liver abscess: risk and prognosis. Clin Infect Dis 2007;44:1194-1201.
29. Kaplan GG, Gregson DB, Laupland KB. Population-based study of the epidemiology of and the risk factors for pyogenic liver abscess. Clin Gastroenterol Hepatol 2004;2:1032-1038.
30. Foo N-P, Chen K-T, Lin H-J, et al. Characteristics of pyogenic liver abscess patients with and without diabetes mellitus. Am J Gastroenterol 2010;105:328-335.
31. Huang WK, Chang JWC, See LC, et al. Higher rate of colorectal cancer among patients with pyogenic liver abscess with Klebsiella pneumoniae than those without: an 11-year follow-up study. Colorectal Dis 2012;14:e794-e801.
32. Mohan S, Talwar N, Chaudhary A, et al. Liver abscess: a clinicopathological analysis of 82 cases. Int Surg 2006;91:228-233.
33. Lodhi S, Sarwari AR, Muzammil M, et al. Features distinguishing amoebic from pyogenic liver abscess: a review of 577 adult cases. Trop Med Int Health 2004;9:718-723.
34. Shon AS, Bajwa RPS, Russo TA. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence 2013;4:107-118.
35. Tian LT, Yao K, Zhang XY, et al. Liver abscesses in adult patients with and without diabetes mellitus: an analysis of the clinical characteristics, features of the causative pathogens, outcomes and predictors of fatality: a report based on a large population, retrospective study in China. Clin Microbiol Infect 2012;18:E314-E330.
36. Kern P, Ammon A, Kron M, et al. Risk factors for alveolar echinococcosis in humans. Emerg Infect Dis 2004;10:2088-2093.
37. Nunnari G, Pinzone MR, Gruttadauria S, et al. Hepatic echinococcosis: clinical and therapeutic aspects. World J Gastroenterol 2012;18:1448-1458.
38. Kern P, Wen H, Sato N, et al. WHO classification of alveolar echinococcosis: principles and application Parasitol Int 2006;55(Suppl):S283-S287.
39. Craig P. Echinococcus multilocularis. Curr Opin Infect Dis 2003;16:437-444.
40. Charlesworth P, Ade-Ajayi N, Davenport M. Natural history and long-term follow-up of antenatally detected liver cysts. J Pediatr Surg 2007;42:494-499.
41. Redston MS, Wanless IR. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies. Mod Pathol 1996;9:233-237.
42. Larssen TB, Rorvik J, Hoff SR, et al. The occurrence of asymptomatic and symptomatic simple hepatic cysts. A prospective, hospital-based study. Clin Radiol 2005;60:1026-1029.
43. Vick DJ, Goodman ZD, Deavers MT, et al. Ciliated hepatic foregut cyst: a study of six cases and review of the literature. Am J Surg Path 1999;23:671-677.
44. Ishak KG, Goodman ZD, Stocker JT. Tumors of the Liver and Intrahepatic Bile Ducts. Washington, DC: Armed Forces Institute of Pathology, 2001.
45. Garcea G, Pattenden CJ, Stephenson J, et al. Nine-year single-center experience with nonparastic liver cysts: diagnosis and management. Dig Dis Sci 2007;52:185-191.
46. Audrezet M-P, Cornec-Le Gall E, Chen J-M, et al. Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Hum Mutat 2012;33:1239-1250.
47. Pirson Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010;17:173-180.
48. Tahvanainen E, Tahvanainen P, Kaariainen H, et al. Polycystic liver and kidney diseases. Ann Med 2005;37:546-555.
49. Cornec-Le Gall E, Audrezet M-P, Chen J-M, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 2013;24:1006-1013.
50. Janssen MJ, Salomon J, Te Morsche RHM, et al. Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease. PLoS ONE 2012;7:e50324.
51. Strazzabosco M, Somlo S. Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology 2011;140:1855-1859.
52. Chandok N. Polycystic liver disease: a clinical review. Ann Hepatol 2012;11:819-826.
53. Gunay-Aygun M, Tuchman M, Font-Montgomery E, et al. PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis. Mol Genet Metab 2010;99:160-173.
54. Kerkar N, Norton K, Suchy FJ. The hepatic fibrocystic diseases. Clin Liver Dis 2006;10:55-71.
55. Zhang DY, Ji ZF, Shen XZ, et al. Caroli's disease: a report of 14 patients and review of the literature. J Dig Dis 2012;13:491-495.
56. Fozard JBJ, Wyatt JI, Hall RI. Epithelial dysplasia in Caroli's disease. Gut 1989;30:1150-1153.
57. Ikenaga N, Chijiiwa K, Otani K, et al. A case of peribiliary cyst presenting with obstructive jaundice. J Gastrointest Surg 2009;13:174-176.
58. Da Ines D, Essamet W, Montoriol PF. Peribiliary cysts. Hepatology 2011;54:2271-2272.
59. Johnson D, Moncure M, Carlton E, et al. Laparoscopic treatment of recurrent hepatic pseudocyst after severe blunt liver trauma. J Trauma 2006;61:1277-1279.
60. Balzan S, Kianmanesh R, Farges O, et al. Right intrahepatic pseudocyst following acute pancreatitis: an unusual location after acute pancreatitis. J Hepato-Biliary-Pancreatic Surg 2005;12:135-137.
61. Seidman JD, Yale-Loehr AJ, Beaver B, et al. Alimentary duplication presenting as an hepatic cyst in a neonate. Am J Surg Pathol 1991;15:695-698.
62. Roesch-Dietlen F, Jimenez-Garcia A, Perez-Morales A, et al. Hepatic endometriosis. Ann Hepatol 2011;10:347-348.
63. Wang C, Miao R, Liu H, et al. Intrahepatic biliary cystadenoma and cystadenocarcinoma: an experience of 30 cases. Dig Liver Dis 2012;44:426-431.
64. Devaney K, Goodman ZD, Ishak KG. Hepatobiliary cystadenoma and cystadenocarcinoma: a light microscopic and immunohistochemical study. Am J Surg Pathol 1994;18:1078-1091.
65. Sang X, Sun Y, Mao Y, et al. Hepatobiliary cystadenomas and cystadenocarcinomas: a report of 33 cases. Liver Int 2011;31:1337-1344.
66. Thomas KT, Welch D, Trueblood A, et al. Effective treatment of biliary cystadenoma. Ann Surg 2005;241:769-773; discussion 773-775.
67. Koffron A, Rao S, Ferrario M, et al. Intrahepatic biliary cystadenoma: role of cyst fluid analysis and surgical management in the laparoscopic era. Surgery 2004;136:926-936.
68. Conrad RJ, Gribbin D, Walker NI, et al. Combined cystic teratoma and hepatoblastoma of the liver. Probable divergent differentiation of an uncommitted hepatic precursor cell. Cancer 1993;72:2910-2913.
69. Morinaga S, Nishiya H, Inafuku T. Yolk sac tumor combined with hepatocellular carcinoma. Arch Pathol Lab Med 1996;120:687-690.
70. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol 1983;14:512-537.
71. Miettinen M, Fletcher CDM, Kindblom LG, et al. Mesenchymal tumours of the liver. In Bosman FT, Carneiro F, Hruban RH, et al, eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2010:241-250.
72. Stringer MD, Alizai NK. Mesenchymal hamartoma of the liver: a systematic review. J Pediatr Surg 2005;40:1681-1690.
73. Yesim G, Gupse T, Zafer U, et al. Mesenchymal hamartoma of the liver in adulthood: immunohistochemical profiles, clinical and histopathological features in two patients. J Hepatobiliary Pancreat Surg 2005;12:502-507.
74. Cajaiba MM, Sarita-Reyes C, Zambrano E, et al. Mesenchymal hamartoma of the liver associated with features of Beckwith-Wiedemann syndrome and high serum alpha-fetoprotein levels. Pediatr Dev Pathol 2007;10:233-238.
75. Rajaram V, Knezevich S, Bove KE, et al. DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t(11;19)(q11;q13.4) translocation. Genes Chromosomes Cancer 2007;46:508-513.
76. Shintaku M, Watanabe K. Mesenchymal hamartoma of the liver: a proliferative lesion of possible hepatic stellate cell (Ito cell) origin. Pathol Res Pract 2010;206:532-536.
77. Nault J-C, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013;144:888-902.
78. Bioulac-Sage P, Balabaud C, Wanless I. Focal nodular hyperplasia and hepatocellular adenoma. In Bosman FT, Carneiro F, Hruban RH, et al eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2010:198-204.
79. Ehren H, Mahour GH, Isaacs H, Jr. Benign liver tumors in infancy and childhood. Report of 48 cases. Am J Surg 1983;145:325-329.
80. Sakellariou S, Al-Hussaini H, Scalori A, et al. Hepatocellular adenoma in glycogen storage disorder type I: a clinicopathological and molecular study. Histopathology 2012;60:E58-E65.
81. Resnick MB, Kozakewich HP, Perez-Atayde AR. Hepatic adenoma in the pediatric age group. Clinicopathological observations and assessment of cell proliferative activity. Am J Surg Pathol 1995;19:1181-1190.
82. Bellamy COC, Maxwell RS, Prost S, et al. The value of immunophenotyping hepatocellular adenomas: consecutive resections at one UK centre. Histopathology 2013;62:431-435.
83. Evason KJ, Grenert JP, Ferrell LD, et al. Atypical hepatocellular adenoma-like neoplasms with -catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol 2013;44:750-758.
84. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007;46:740-748.
85. Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis: an entity distinct from liver cell adenoma? Gastroenterology 1985;89:1132-1138.
86. Jeannot E, Poussin K, Chiche L, et al. Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1 alpha-mutated hepatocellular adenoma. Cancer Res 2007;67:2611-2616.
87. Ichikawa T, Federle MP, Grazioli L, et al. Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology 2000;214:861-868.
88. Ronot M, Bahrami S, Calderaro J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 2011;53:1182-1191.
89. Ahmad I, Iyer A, Marginean CE, et al. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma. Hum Pathol 2009;40:726-734.
90. Mounajjed T, Wu T-T. Telangiectatic variant of hepatic adenoma: clinicopathologic features and correlation between liver needle biopsy and resection. Am J Surg Pathol 2011;35:1356-1363.
91. Bioulac-Sage P, Balabaud C, Bedossa P, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 2007;46:521-527.
92. Wilkens L, Bredt M, Flemming P, et al. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol 2001;193:476-482.
93. Shen Y-H, Fan J, Wu Z-Q, et al. Focal nodular hyperplasia of the liver in 86 patients. Hepatobiliary Pancreat Dis Int 2007;6:52-57.
94. Reymond D, Plaschkes J, Luthy AR, et al. Focal nodular hyperplasia of the liver in children: review of follow-up and outcome. J Pediatr Surg 1995;30:1590-1593.
95. Ibarrola C, Castellano VM, Colina F. Focal hyperplastic hepatocellular nodules in hepatic venous outflow obstruction: a clinicopathological study of four patients and 24 nodules. Histopathology 2004;44:172-179.
96. Brenard R, Chapaux X, Deltenre P, et al. Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. Eur J Gastroenterol Hepatol 2010;22:1253-1259.
97. Choi JY, Lee HC, Yim JH, et al. Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis. J Gastroenterol Hepatol 2011;26:1004-1009.
98. Masetti R, Colecchia A, Rondelli R, et al. Benign hepatic nodular lesions after treatment for childhood cancer. J Pediatr Gastroenterol Nutr 2013;56:151-155.
99. Nguyen BN, Flejou JF, Terris B, et al. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999;23:1441-1454.
100. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005;128:1211-1218.
101. Kuo Y-H, Wang J-H, Lu S-N, et al. Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. J Clin Ultrasound 2009;37:132-137.
102. Bioulac-Sage P, Laumonier H, Rullier A, et al. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int 2009;29:459-465.
103. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of hepatocellular nodules. Hepatology 1990;11:787-797.
104. Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010;56:430-439.
105. Ryan P, Nanji S, Pollett A, et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol 2010;34:784-791.
106. Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010;24:1171-1176.
107. Morris JM, Oien KA, McMahon M, et al. Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series. Eur J Gastroenterol Hepatol 2010;22:1001-1005.
108. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006;44:7-14.
109. Borzio M, Fargion S, Borzio F, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003;39:208-214.
110. Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 2006;106:636-647.
111. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22:983-993.
112. Theise ND. Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Semin Liver Dis 1995;15:360-371.
113. Natarajan S, Theise ND, Thung SN, et al. Large-cell change of hepatocytes in cirrhosis may represent a reaction to prolonged cholestasis. Am J Surg Pathol 1997;21:312-318.
114. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010;30:17-25.
115. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005;25:16-27.
116. Quaglia A, Jutand MA, Dhillon A, et al. Classification tool for the systematic histological assessment of hepatocellular carcinoma, macroregenerative nodules, and dysplastic nodules in cirrhotic liver. World J Gastroenterol 2005;11:6262-6268.
117. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006;30:1405-1411.
118. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2010;30:3-16.
119. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211.
120. Schlesinger S, Aleksandrova K, Pischon T, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer 2013;132:645-657.
121. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-243.
122. Theise ND, Curado MP, Franceschi S, et al. Hepatocellular carcinoma. In Bosman FT, Carneiro F, Hruban RH, et al. eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2010:205-216.
123. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
124. Katoh H, Shibata T, Kokubu A, et al. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol 2005;43:863-874.
125. Yam JW, Wong CM, Ng IO-L. Molecular and functional genetics of hepatocellular carcinoma. Front Biosci 2010;2:117-134.
126. Nishida N, Nishimura T, Nagasaka T, et al. Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res 2007;67:4586-4594.
127. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006;25:3778-3786.
128. Nishida N, Kudo M. Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma Oncology 2013;84(Suppl 1):93-97.
129. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers: a clinicopathologic study of 804 North American patients. Am J Clin Pathol 1996;105:65-75.
130. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005;25:143-154.
131. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006;26:385-390.
132. Okuda H, Nakanishi T, Takatsu K, et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000;88:544-549.
133. Edge SE, Byrd DR, Carducci MA, et al, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010.
134. Edmonson HA, Steiner PE. Primary carcinoma of the liver. Cancer 1954;7:462-503.
135. Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995;76:579-588.
136. Lauwers GY, Terris B, Balis UJ, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 2002;26:23-34.
137. Roberts CC, Colby TV, Batts KP. Carcinoma of the stomoach with hepatocyte differentiation (hepatoid adenocarcinoma). Mayo Clin Proc 1997;72:1154-1160.
138. Salamao M, Remotti H, Vaughn R, et al. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012;43:737-746.
139. Guigui B, Mavier P, Lescs MC, et al. Copper and copper-binding protein in liver tumors. Cancer 1988;61:1155-1158.
140. Maeda T, Adachi E, Kajiyama K, et al. Spindle cell hepatocellular carcinoma: a cliniopathologic and immunohistochemical analysis of 15 cases. Cancer 1996;77:51-57.
141. Lugli A, Tornillo L, Mirlacher M, et al. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol 2004;122:721-727.
142. Sugiki T, Yamamoto M, Aruga A, et al. Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1. J Surg Oncol 2004;88:104-107.
143. Chu PG, Ishizawa S, Wu E, et al. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002;26:978-988.
144. Chan ES, Yeh MM. The use of immunohistochemistry in liver tumors. Clin Liver Dis 2010;14:687-703.
145. Lau SK, Prakash S, Geller SA, et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002;33:1175-1181.
146. Mounajjed T, Zhang L, Wu T-T. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum Pathol 2013;44:542-550.
147. Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol 2012;7:149.
148. Yan BC, Gong C, Song J, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol 2010;34:1147-1154.
149. Varma V, Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv Anat Pathol 2004;11:239-249.
150. Lei J-Y, Bourne PA, diSant'Agnese PA, et al. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol 2006;125:519-525.
151. Singhal A, Jayaraman M, Dhanasekaran DN, et al. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol 2012;82:116-140.
152. Tateishi R, Omata M. Hepatocellular carcinoma in 2011: genomics in hepatocellular carcinoma-a big step forward. Nat Rev Gastroenterol Hepatol 2012;9:69-70.
153. Park YN, Roncalli M. Large liver cell dysplasia: a controversial entity. J Hepatol 2006;45:734-743.
154. Krishnamurthy SC, Dutta V, Pai SA, et al. Primary carcinoid tumor of the liver: report of four resected cases including one with gastrin production. J Surg Oncol 1996;62:218-221.
155. Zhao M, Lauissue JA, Zimmerman A. Neuroendocrine differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol Histopathol 1993;8:617-626.
156. Lang H, Sotiropoulos GC, Brokalaki EI, et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007;205:27-36.
157. Couto OFM, Dvorchik I, Carr BI. Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 2007;52:3285-3289.
158. Escartin A, Sapisochin G, Bilbao I, et al. Recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 2007;39:2308-2310.
159. Arista-Nasr J, Gutierrez-Villalobos L, Nuncio J, et al. Fibrolamellar hepatocellular carcinoma in mexican patients. Pathol Oncol Res 2002;8:133-137.
160. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004;39:798-803.
161. Liu S, Chan KW, Wang B, et al. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol 2009;104:2617-2624; quiz 2625.
162. Kakar S, Burgart L, Batts K, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005;18:1417-1423.
163. Ruffin IM. Fibrolamellar hepatoma. Am J Gastroenterol 1990;85:577-581.
164. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 1997;26:877-883.
165. Malouf GG, Brugieres L, Le Deley M-C, et al. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer 2012;118:4981-4990.
166. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 2007;14:217-223.
167. Ichikawa T, Federle MP, Grazioli L, et al. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology 1999;213:352-561.
168. Blachar A, Federle MP, Ferris JV, et al. Radiologists' performance in the diagnosis of liver tumors with central scars by using specific CT criteria. Radiology 2002;223:532-539.
169. Saxena R, Humphreys S, Williams R, et al. Nodular hyperplasia surrounding fibrolamellar carcinoma: a zone of arterialized liver parenchyma. Histopathology 1994;25:275-278.
170. Kakar S, Chen X, Ho C, et al. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Mod Pathol 2009;22:134-141.
171. Kannangai R, Vivekanandan P, Martinez-Murillo F, et al. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 2007;38:639-644.
172. Vivekanandan P, Micchelli STL, Torbenson M. Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. Hum Pathol 2009;40:293-299.
173. Honda K, Sbisa E, Tullo A, et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 1998;77:776-782.
174. Kannangai R, Wang J, Liu QZ, et al. Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer 2005;35:53-60.
175. Trankenschuh W, Puls F, Christgen M, et al. Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. PLoS One 2010;5:e13688.
176. Vivekanandan P, Daniel H, Yeh MM, et al. Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas. Mod Pathol 2010;23:790-798.
177. An T, Ghatak N, Kastner R, et al. Hyaline globules and intracellular lumina in a hepatocellular carcinoma. Am J Clin Pathol 1983;79:392-396.
178. Payne CM, Nagle RB, Paplanus SH, et al. Fibrolamellar carcinoma of liver: a primary malignant oncocytic carcinoid? Ultrastruct Pathol 1986;10:539-552.
179. Abdul-Al HM, Wang G, Makhlouf HR, et al. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma. Int J Surg Pathol 2010;18:313-318.
180. Schoedel KE, Tyner VZ, Kim TH, et al. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Mod Pathol 2003;16:14-21.
181. Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. [see comment]. Am J Clin Pathol 2005;124:512-518.
182. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 1988;19:784-794.
183. Van Eyken P, Sciot R, Brock P, et al. Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology 1990;17:101-107.
184. Kaplan JS, Hoda RS. Clear cell variant of fibrolamellar hepatocellular carcinoma: diagnosis of recurrence by fine-needle aspiration. Diagn Cytopathol 2007;35:459-462.
185. Cheuk W, Chan JK. Clear cell variant of fibrolamellar carcinoma of the liver. Arch Pathol Lab Med 2001;125:1235-1238.
186. Tanaka K, Honna T, Kitano Y, et al. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report. J Clin Pathol 2005;58:884-887.
187. Okada K, Kim YI, Nakashima K, et al. Fibrolamellar hepatocellular carcinoma coexistent with a hepatocellular carcinoma of common type: report of a case. Surg Today 1993;23:626-631.
188. Yamamoto H, Watanabe K, Nagata M, et al. Transformation of fibrolamellar carcinoma to common hepatocellular carcinoma in the recurrent lesions of the rectum and the residual liver: a case report. Jpn J Clin Oncol 1999;29:445-447.
189. Ang CS, Kelley RK, Choti MA, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 2013;6:3-9.
190. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006;106:1331-1338.
191. El-Gazzaz G, Wong W, El-Hadary MK, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma Transpl Int 2000;13(Suppl 1):S406-S409.
192. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003;97:2006-2012.
193. Omata M, Peters RL, Tatter D. Sclerosing hepatic carcinoma: relationship to hypercalcemia. Liver 1981;1:33-49.
194. Malouf G, Falissard B, Azoulay D, et al. Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts? J Clin Pathol 2009;62:519-524.
195. Lopez-Terrada D, Zimmermann A. Current issues and controversies in the classification of pediatric hepatocellular tumors. Pediatr Blood Cancer 2012;59:780-784.
196. Zimmerman A, Saxena R. Hepatoblastoma. In Bosman FT, Carneiro F, Hruban RH, et al. eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2010:228-235.
197. Wang YX, Liu H. Adult hepatoblastoma: systemic review of the English literature. Dig Surg 2012;29:323-330.
198. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer 2012;59:776-779.
199. Tomlinson GE, Kappler R. Genetics and epigenetics of hepatoblastoma. Pediatr Blood Cancer 2012;59:785-792.
200. McCarville MB, Roebuck DJ. Diagnosis and staging of hepatoblastoma: imaging aspects. Pediatr Blood Cancer 2012;59:793-799.
201. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, et al. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009;52:328-334.
202. Lopez-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol 2009;40:783-794.
203. D'Antiga L, Vallortigara F, Cillo U, et al. Features predicting unresectability in hepatoblastoma. Cancer 2007;110:1050-1058.
204. Finegold MJ, Lopez-Terrada DH, Bowen J, et al. Protocol for the examination of specimens from pediatric patients with hepatoblastoma. Arch Pathol Lab Med 2007;131:520-529.
205. Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group. J Clin Oncol 2011;29:3301-3306.
206. Cross SS, Variend S. Combined hepatoblastoma and yolk sac tumor of the liver. Cancer 1992;69:1323-1326.
207. Wang LL, Filippi RZ, Zurakowski D, et al. Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study. Am J Surg Pathol 2010;34:287-299.
208. Narita T, Moriyama Y, Ito Y. Endodermal sinus (yolk sac) tumour of the liver. A case report and review of the literature. J Pathol 1988;155:41-47.
209. Rowland JM. Hepatoblastoma: assessment of criteria for histologic classification. Med Pediatr Oncol 2002;39:478-483.
210. Rocken C, Pross M, Brucks U, et al. Cholangiocarcinoma occurring in a liver with multiple bile duct hamartomas (von Meyenburg complexes). Arch Pathol Lab Med 2000;124:1704-1706.
211. Allaire GS, Rabin L, Ishak KG, et al. Bile duct adenoma. A study of 152 cases. Am J Surg Pathol 1988;12:708-715.
212. Hughes NR, Goodman ZD, Bhathal PS. An immunohistochemical profile of the so-called bile duct adenoma: clues to pathogenesis. Am J Surg Pathol 2010;34:1312-1318.
213. Nakanuma Y, Curado MP, Franceschi S, et al. Intrahepatic cholangiocarcinoma. In Bosman FT, Carneiro F, Hruban RH, et al eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2010:217-224.
214. Charbel H, Al-Kawas FH. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep 2011;13:182-187.
215. Witjes CDM, Karim-Kos HE, Visser O, et al. Intrahepatic cholangiocarcinoma in a low endemic area: rising incidence and improved survival. HPB 2012;14:777-781.
216. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472-477.
217. McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int 2006;26:1047-1053.
218. Fu XH, Tang ZH, Zong M, et al. Clinicopathologic features, diagnosis and surgical treatment of intrahepatic cholangiocarcinoma in 104 patients. Hepatobiliary Pancreat Dis Int 2004;3:279-283.
219. Lacomis JM, Baron RL, Oliver JH, 3rd, et al. Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology 1997;203:98-104.
220. Aloia TA, Charnsangavej C, Faria S, et al. High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg 2007;193:702-706.
221. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012;57:69-76.
222. Shen C, Li S, Zheng S, et al. Tissue parasitic helminthiases are prevalent at Cheongjin, North Korea. Korean J Parasitol 2007;45:139-144.
223. Zhang R, Gao S, Geng Y, et al. Epidemiological study on Clonorchis sinensis infection in Shenzhen area of Zhujiang delta in China. Parasitol Res 2007;101:179-183.
224. Lim MK, Ju Y-H, Franceschi S, et al. Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the Republic of Korea. Am J Trop Med Hyg 2006;75:93-96.
225. Choi D, Lim JH, Lee KT, et al. Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea. J Hepatol 2006;44:1066-1073.
226. Kassahun WT, Kahn T, Wittekind C, et al. Caroli's disease: liver resection and liver transplantation. Experience in 33 patients. Surgery 2005;138:888-898.
227. Nakanuma Y, Sasaki M, Terada T, et al. Intrahepatic peribiliary glands of humans. II. Pathological spectrum. J Gastroenterol Hepatol 1994;9:80-86.
228. Di Stefano F, Verna N, Balatsinou L, et al. Genetic hemochromatosis with normal transferrin saturation in a man with cholangiocarcinoma and yellow nail syndrome. J Gastroenterol Hepatol 2003;18:1221-1222.
229. Morcos M, Dubois S, Bralet MP, et al. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum. Am J Clin Pathol 2001;116:738-743.
230. Zhou H, Ortiz-Pallardo ME, Ko Y, et al. Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer 2000;88:2668-2676.
231. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007;5:1221-1228.
232. Okuda K, Kubo Y, Okazaki N, et al. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer 1977;39:232-246.
233. Altaee MY, Johnson PJ, Farrant JM, et al. Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 1991;68:2051-2055.
234. Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004;24:127-1237.
235. Celli A, Que FG. Dysregulation of apoptosis in the cholangiopathies and cholangiocarcinoma. Semin Liver Dis 1998;18:177-185.
236. Hsu M, Sasaki M, Igarashi S, et al. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer 2013;119:1669-1774.
237. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013;32:3091-3100.
238. Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013;44:1216-1222.
239. Kang YK, Kim WH, Lee HW, et al. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999;79:477-483.
240. Kato H, Tabata M, Azumi Y, et al. Proposal for a morphological classification of intraductal papillary neoplasm of the bile duct (IPN-B). J Hepatobiliary Pancreat Sci 2013;20:165-172.
241. Naito Y, Kusano H, Nakashima O, et al. Intraductal neoplasm of the intrahepatic bile duct: clinicopathological study of 24 cases. World J Gastroenterol 2012;18:3673-3680.
242. Rocha FG, Lee H, Katabi N, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology 2012;56:1352-1360.
243. Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013;153:811-818.
244. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140-3145.
245. Theise ND, Nakashima O, Park YN, et al. Combined hepatocellular-cholangiocarcinoma. In Bosman FT, Carneiro F, Hruban RH, et al, eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2010:225-227.
246. Akiba J, Nakashima O, Hattori S, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013;37:496-505.
247. Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003;33:283-287.
248. Yu X-H, Xu L-B, Zeng H, et al. Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2011;10:620-625.
249. Coulouarn C, Cavard C, Rubbia-Brandt L, et al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGF signaling pathways. Carcinogenesis 2012;33:1791-1796.
250. Ikeda H, Harada K, Sato Y, et al. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol 2013;140:329-340.
251. Zhan Q, Shen B-Y, Deng X-X, et al. Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center. J Hepatobiliary Sci 2012;19:361-369.
252. Sapisochin G, Fidelman N, Roberts JP, et al. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 2011;17:934-942.
253. Maganty K, Levi D, Moon J, et al. Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation. Dig Dis Sci 2010;55:3597-3601.
254. Hwang S, Lee Y-J, Lee S-G, et al. Surgical treatment of primary neuroendocrine tumors of the liver. J Gastrointest Surg 2008;12:725-730.
255. Zhu H, Sun K, Ward SC, et al. Primary hepatic signet ring cell neuroendocrine tumor: a case report with literature review. Semin Liver Dis 2010;30:422-428.
256. Bioulac-Sage P, Laumonier H, Laurent C, et al. Benign and malignant vascular tumors of the liver in adults. Semin Liver Dis 2008;28:302-314.
257. Takahashi T, Katoh H, Dohke M, et al. A giant hepatic hemangioma with secondary portal hypertension: a case report of successful surgical treatment. Hepatogastroenterology 1997;44:1212-1214.
258. Watzke HH, Linkesch W, Hay U. Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal. J Clin Gastroenterol 1989;11:347-350.
259. Shimizu M, Miura J, Itoh H, et al. Hepatic giant cavernous hemangioma with microangiopathic hemolytic anemia and consumption coagulopathy. Am J Gastroenterol 1990;85:1411-1413.
260. Saegusa T, Ito K, Oba N, et al. Enlargement of multiple cavernous hemangioma of the liver in association with pregnancy. Intern Med 1995;34:207-211.
261. Schillaci O, Filippi L, Danieli R, et al. Single-photon emission computed tomography/computed tomography in abdominal diseases. Semin Nucl Med 2007;37:48-61.
262. Kulungowski AM, Alomari AI, Chawla A, et al. Lessons from a liver hemangioma registry: subtype classification. J Pediatr Surg 2012;47:165-170.
263. Hornick JL, Fletcher CD. Intraabdominal cystic lymphangiomas obscured by marked superimposed reactive changes: clinicopathological analysis of a series. Hum Pathol 2005;36:426-432.
264. Diment J, Yurim O, Pappo O. Infantile hemangioendothelioma of the liver in an adult. Arch Pathol Lab Med 2001;125:931-932.
265. Selby DM, Stocker JT, Waclawiw MA, et al. Infantile hemangioendothelioma of the liver. Hepatology 1994;20:39-45.
266. Keslar PJ, Buck JL, Selby DM. From the archives of the AFIP. Infantile hemangioendothelioma of the liver revisited. Radiographics 1993;13:657-670.
267. Dehner LP, Ishak KG. Vascular tumors of the liver in infants and children. A study of 30 cases and review of the literature. Arch Pathol 1971;92:101-111.
268. Mo JQ, Dimashkieh HH, Bove KE. GLUT1 endothelial reactivity distinguishes hepatic infantile hemangioma from congenital hepatic vascular malformation with associated capillary proliferation. Hum Pathol 2004;35:200-209.
269. Neri M, Bello S, Bonsignore A, et al. Anabolic androgenic steroids abuse and liver toxicity. Mini Rev Med Chem 2011;11:430-437.
270. Perarnau J-M, Bacq Y. Hepatic vascular involvement related to pregnancy, oral contraceptives, and estrogen replacement therapy. Semin Liver Dis 2008;28:315-327.
271. Choi S-K, Jin J-S, Cho S-G, et al. Spontaneous liver rupture in a patient with peliosis hepatis: a case report. World J Gastroenterol 2009;15:5493-5497.
272. Infante PF, Petty SE, Groth DH, et al. Vinyl chloride propellant in hair spray and angiosarcoma of the liver among hairdressers and barbers: case reports. Int J Occup Environ Health 2009;15:36-42.
273. Hollstein M, Marion MJ, Lehman T, et al. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994;15:1-3.
274. Koyama T, Fletcher JG, Johnson CD, et al. Primary hepatic angiosarcoma: findings at CT and MR imaging. Radiology 2002;222:667-673.
275. Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 1996;77:2400-2406.
276. Duan XF, Li Q. Primary hepatic angiosarcoma: a retrospective analysis of 6 cases. J Dig Dis 2012;13:381-385.
277. Orlando G, Adam R, Mirza D, et al">276 Orlando G, Adam R, Mirza D, et al. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation-the European Liver Transplant Registry experience. Transplantation 2013;95:872-827.
278. Makhlouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendotheliomas of the liver: a clinicopathologic study of 137 cases. Cancer 1999;85:562-582.
279. Mermuys K, Vanhoenacker PK, Roskams T, et al. Epithelioid hemangioendothelioma of the liver: radiologic-pathologic correlation. Abdom Imaging 2004;29:221-223.
280. Demetris AJ, Minervini M, Raikow RB, et al. Hepatic epithelioid hemangioendothelioma: biological questions based on pattern of recurrence in an allograft and tumor immunophenotype. Am J Surg Pathol 1997;21:263-270.
281. Fujii T, Zen Y, Sato Y, et al. Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. Mod Pathol 2008;21:125-130.
282. Meis-Kindblom JM, Kindblom LG. Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol 1998;22:683-697.
283. Wang L-R, Zhou J-M, Zhao Y-M, et al. Clinical experience with primary hepatic epithelioid hemangioendothelioma: retrospective study of 33 patients. World J Surg 2012;36:2677-2683.
284. Cardinal J, de Vera ME, Marsh JW, et al. Treatment of hepatic epithelioid hemangioendothelioma: a single-institution experience with 25 cases. Arch Surg 2009;144:1035-1039.
285. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010;10:707-719.
286. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010;103:416-422.
287. Ioachim HL, Adsay V, Giancotti FR, et al. Kaposi's sarcoma of internal organs. A multiparameter study of 86 cases. Cancer 1995;75:1376-1385.
288. Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999;79:243-251.
289. Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett 2013;305:150-162.
290. Ramani P, Shah A. Lymphangiomatosis. Histologic and immunohistochemical analysis of four cases. Am J Surg Pathol 1993;17:329-335.
291. Matsumoto T, Ojima H, Akishima-Fukasawa Y, et al. Solitary hepatic lymphangioma: report of a case. Surg Today 2010;40:883-889.
292. O'Sullivan DA, Torres VE, de Groen PC, et al. Hepatic lymphangiomatosis mimicking polycystic liver disease. Mayo Clin Proc 1998;73:1188-1192.
293. Ooi CY, Brody D, Wong R, et al. Liver transplantation for massive hepatic lymphangiomatosis in a child. J Pediatr Gastroenterol Nutr 2011;52:366-369.
294. Ra SH, Bradley RF, Fishbein MC, et al. Recurrent hepatic lymphangiomatosis after orthotopic liver transplantation. Liver Transpl 2007;13:1593-1597.
295. Ding G-H, Liu Y, Wu M-C, et al. Diagnosis and treatment of hepatic angiomyolipoma. J Surg Oncol 2011;103:807-812.
296. Petrolla AA, Xin W. Hepatic angiomyolipoma. Arch Pathol Lab Med 2008;132:1679-1682.
297. Black ME, Hedgire SS, Camposano S, et al. Hepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis. Clin Genet 2012;82:552-557.
298. Nonomura A, Enomoto Y, Takeda M, et al. Angiomyolipoma of the liver: a reappraisal of morphological features and delineation of new characteristic histological features from the clinicopathological findings of 55 tumours in 47 patients. Histopathology 2012;61:863-880.
299. Wanless IR. Benign liver tumors. Clin Liver Dis 2002;6:513-526, ix.
300. Yoshimitsu K, Irie H, Kakihara D, et al. Postgastrectomy development or accentuation of focal fatty change in segment IV of the liver: correlation with the presence of aberrant venous branches of the parabiliary venous plexus. J Clin Gastroenterol 2007;41:507-512.
301. Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumour. In Fletcher CDM, Bridge JA, Hogendoorn CW, et al, eds. WHO Classification of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press, 2013:83-84.
302. Coffin CM, Watterson J, Priest JR, et al. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995;19:859-872.
303. Ahn KS, Kang KJ, Kim YH, et al. Inflammatory pseudotumors mimicking intrahepatic cholangiocarcinoma of the liver; IgG4-positivity and its clinical significance. J Hepatobiliary Pancreat Sci 2012;19:405-412.
304. Saab ST, Hornick JL, Fletcher CD, et al. IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link? Mod Pathol 2011;24:606-612.
305. Tsou YK, Lin CJ, Liu NJ, et al. Inflammatory pseudotumor of the liver: report of eight cases, including three unusual cases, and a literature review. J Gastroenterol Hepatol 2007;22:2143-2147.
306. Schnelldorfer T, Chavin KD, Lin A, et al. Inflammatory myofibroblastic tumor of the liver. J Hepatobiliary Pancreat Surg 2007;14:421-423.
307. Tang L, Lai ECH, Cong W-M, et al. Inflammatory myofibroblastic tumor of the liver: a cohort study. World J Surg 2010;34:309-313.
308. Shia J, Chen W, Tang LH, et al. Extranodal follicular dendritic cell sarcoma: clinical, pathologic, and histogenetic characteristics of an underrecognized disease entity. Virchows Arch 2006;449:148-158.
309. Deniz K, Coban G. Solitary necrotic nodule of the liver: always benign? J Gastrointest Surg 2010;14:536-540.
310. Mesenas SJ, Ng KY, Raj P, et al. Primary leiomyoma of the liver. Singapore Med J 2000;41:129-131.
311. Raber EL, Cheng A-L, Dong W-F, et al. Primary hepatic leiomyoma in a transplant patient: characterization with magnetic resonance imaging. Transplantation 2012;93:e4-e5.
312. Yoon GS, Kang GH, Kim OJ. Primary myxoid leiomyoma of the liver. Arch Pathol Lab Med 1998;122:1112-1115.
313. Moran CA, Ishak KG, Goodman ZD. Solitary fibrous tumor of the liver: a clinicopathologic and immunohistochemical study of nine cases. Ann Diagn Pathol 1998;2:19-24.
314. Bokshan SL, Doyle M, Becker N, et al. Hepatic hemangiopericytoma/solitary fibrous tumor: a review of our current understanding and case study. J Gastrointest Surg 2012;16:2170-2176.
315. Shehata BM, Gupta NA, Katzenstein HM, et al. Undifferentiated embryonal sarcoma of the liver is associated with mesenchymal hamartoma and multiple chromosomal abnormalities: a review of eleven cases. Pediatr Dev Pathol 2011;14:111-116.
316. Lack EE, Schloo BL, Azumi N, et al. Undifferentiated (embryonal) sarcoma of the liver. Clinical and pathologic study of 16 cases with emphasis on immunohistochemical features. Am J Surg Pathol 1991;15:1-16.
317. Stocker JT, Ishak KG. Undifferentiated (embryonal) sarcoma of the liver: report of 31 cases. Cancer 1978;42:336-348.
318. May LT, Wang M, Albano E, et al. Undifferentiated sarcoma of the liver: a single institution experience using a uniform treatment approach. J Pediatr Hematol Oncol 2012;34:e114-e116.
319. Noguchi K, Yokoo H, Nakanishi K, et al. A long-term survival case of adult undifferentiated embryonal sarcoma of liver. World J Surg Oncol 2012;10:65.
320. Trobaugh-Lotrario AD, Finegold MJ, Feusner JH. Rhabdoid tumors of the liver: rare, aggressive, and poorly responsive to standard cytotoxic chemotherapy. Pediatr Blood Cancer 2011;57:423-428.
321. Pinson CW, Lopez RR, Ivancev K, et al. Resection of primary hepatic malignant fibrous histiocytoma, fibrosarcoma, and leiomyosarcoma. South Med J 1994;87:384-391.
322. Yao D, Dai C. Clinical characteristics of the primary hepatic malignant fibrous histiocytoma in China: case report and review of the literature. World J Surg Oncol 2012;10:2.
323. Yin L, Lai CHE, Li A-J, et al. Primary hepatic malignant fibrous histiocytoma: diagnostic pitfalls and therapeutic challenge. Hepatogastroenterology 2011;58:887-891.
324. Gates LK, Jr., Cameron AJ, Nagorney DM, et al. Primary leiomyosarcoma of the liver mimicking liver abscess. Am J Gastroenterol 1995;90:649-652.
325. Miettinen M. Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma. Arch Pathol Lab Med 1988;112:637-640.
326. Chi M, Dudek AZ, Wind KP. Primary hepatic leiomyosarcoma in adults: analysis of prognostic factors. Onkologie 2012;35:210-214.
327. Schoofs G, Braeye L, Vanheste R, et al. Hepatic rhabdomyosarcoma in an adult: a rare primary malignant liver tumor. Case report and literature review. Acta Gastroenterol Belg 2011;74:576-581.
328. Stocker JT. Hepatic tumors in children. Clin Liver Dis 2001;5:259-281.
329. Ruymann FB, Raney RB, Jr., Crist WM, et al. Rhabdomyosarcoma of the biliary tree in childhood. A report from the Intergroup Rhabdomyosarcoma Study. Cancer 1985;56:575-581.
330. Nelson V, Fernandes NF, Woolf GM, et al. Primary liposarcoma of the liver: a case report and review of literature. Arch Pathol Lab Med 2001;125:410-412.
331. Govender D, Rughubar KN. Primary hepatic osteosarcoma: case report and literature review. Pathology 1998;30:323-325.
332. Lederman SM, Martin EC, Laffey KT, et al. Hepatic neurofibromatosis, malignant schwannoma, and angiosarcoma in von Recklinghausen's disease. Gastroenterology 1987;92:234-239.
333. Jaffe ES, Muller-Hermelink HK, Delabie J, et al. Lymphoma of the liver. In Bosman FT, Carneiro F, Hruban RH, et al. eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2010:239-240.
334. Chi M, Tandra P, Jallad B, et al. A primary biliary diffuse large B-cell lymphoma mimicking Klatskin Tumor in an HIV patient. Onkologie 2011;34:555-556.
335. Kikuma K, Watanabe J, Oshiro Y, et al. Etiological factors in primary hepatic B-cell lymphoma. Virchows Archiv 2012;460:379-387.
336. Cameron AM, Truty J, Truell J, et al. Fulminant hepatic failure from primary hepatic lymphoma: successful treatment with orthotopic liver transplantation and chemotherapy. Transplantation 2005;80:993-996.
337. Khan SM, Cottrell BJ, Millward-Sadler GH, et al. T-cell-rich B-cell lymphoma presenting as liver disease. Histopathology 1993;23:217-224.
338. Castroagudin JF, Gonzalez-Quintela A, Fraga M, et al. Presentation of T-cell-rich B-cell lymphoma mimicking acute hepatitis. Hepatogastroenterology 1999;46:1710-1713.
339. Schober T, Framke T, Kreipe H, et al. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 2013;95:240-246.
340. Jagadeesh D, Woda BA, Draper J, et al. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012;13:122-136.
341. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2010;149:675-692.
342. Navarro J-T, Ribera J-M, Mate J-L, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003;44:531-533.
343. Abdalla EK, Alonsozana EL, Stamberg J, et al. Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma. Leukemia 1997;11:1367-1372.
344. Baschinsky DY, Weidner N, Baker PB, et al. Primary hepatic anaplastic large-cell lymphoma of T-cell phenotype in acquired immunodeficiency syndrome: a report of an autopsy case and review of the literature. Am J Gastroenterol 2001;96:227-232.
345. Xu L, Jeudy J, Burke AP. Ectopic hepatic tissue presenting as right atrial mass. Hum Pathol 2012;43:958-960.
346. Kuo F-Y, Swanson PE, Yeh MM. Pancreatic acinar tissue in liver explants: a morphologic and immunohistochemical study. Am J Surg Pathol 2009;33:66-71.
347. Rother M, Dufour J-F, Schnuriger B. An uncommon cause of a focal liver lesion. Post-traumatic splenosis. Gastroenterology 2013;144:510.
348. Flemming P, Frerker M, Klempnauer J, et al. Benign schwannoma of the liver with cystic changes misinterpreted as hydatid disease. Hepatogastroenterology 1998;45:1764-1766.
349. Ghalib R, Howard T, Lowell J, et al. Plexiform neurofibromatosis of the liver: case report and review of the literature. Hepatology 1995;22:1154-1157.
350. Wagner LM, Garrett JK, Ballard ET, et al. Malignant rhabdoid tumor mimicking hepatoblastoma: a case report and literature review. Pediatr Dev Pathol 2007;10:409-415.
351. Lefkowitch JH. The epidemiology and morphology of primary malignant liver tumors. Surg Clin North Am 1981;61:169-180.
352. Iazobuzio-Donahue C, Ferrell LD. Secondary tumours of the liver. In Bosman FT, Carneiro F, Hruban RH, et al. eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press, 2010:251-253.
353. Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 2008;132:931-939.
354. Stocker JT. Hepatic tumors in children. Clin Liver Dis 2001;5:259-281, viii-ix.
355. Wang SC, Fidelman N, Nakakura EK. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver. Semin Oncol 2013;40:69-74.
356. Riopel MA, Klimstra DS, Godellas CV, et al. Intrabiliary growth of metastatic colonic adenocarcinoma: a pattern of intrahepatic spread easily confused with primary neoplasia of the biliary tract. Am J Surg Pathol 1997;21:1030-1036.
357. Gravel DH, Begin LR, Brisson ML, et al. Metastatic carcinoma resulting in hepar lobatum. Am J Clin Pathol 1996;105:621-627.
358. Harris AC, Ben-Ezra JM, Contos MJ, et al. Malignant lymphoma can present as hepatobiliary disease. Cancer 1996;78:2011-2019.
359. Shehab TM, Kaminski MS, Lok AS. Acute liver failure due to hepatic involvement by hematologic malignancy. Dig Dis Sci 1997;42:1400-1405.
360. Mican JM, Di Bisceglie AM, Fong TL, et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995;22:1163-1170.
361. Georgin-Lavialle S, Lhermitte L, Dubreuil P, et al. Mast cell leukemia. Blood 2013;121:1285-1295.
362. Farrell DJ, Hines JE, Walls AF, et al. Intrahepatic mast cells in chronic liver diseases. Hepatology 1995;22:1175-1181.
363. Kyriakou D, Kouroumalis E, Konsolas J, et al. Systemic mastocytosis: a rare cause of noncirrhotic portal hypertension simulating autoimmune cholangitis-report of four cases. Am J Gastroenterol 1998;93:106-108.
364. Dedic K. Hairy cell leukemia: an autopsy study. Acta Medica (Hradec Kralove) 2003;46:175-177.
365. Andrade RJ, Camargo R, Garcia E, et al. A case of hairy cell leukemia resembling asymptomatic chronic liver disease on presentation. Acta Gastroenterol Belg 1998;61:483-484.
366. Roquet ML, Zafrani ES, Farcet JP, et al. Histopathological lesions of the liver in hairy cell leukemia: a report of 14 cases. Hepatology 1985;5:496-500.